|
|
|
|
LEADER |
01000caa a22002652c 4500 |
001 |
NLM30401530X |
003 |
DE-627 |
005 |
20250226090549.0 |
007 |
cr uuu---uuuuu |
008 |
231225s2020 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1002/adma.201906799
|2 doi
|
028 |
5 |
2 |
|a pubmed25n1013.xml
|
035 |
|
|
|a (DE-627)NLM30401530X
|
035 |
|
|
|a (NLM)31799765
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Li, Yao
|e verfasserin
|4 aut
|
245 |
1 |
2 |
|a A Bioinspired Nanoprobe with Multilevel Responsive T1 -Weighted MR Signal-Amplification Illuminates Ultrasmall Metastases
|
264 |
|
1 |
|c 2020
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 21.10.2020
|
500 |
|
|
|a Date Revised 21.10.2020
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
520 |
|
|
|a Metastasis remains the major cause of death in cancer patients. Thus, there is a need to sensitively detect tumor metastasis, especially ultrasmall metastasis, for early diagnosis and precise treatment of cancer. Herein, an ultrasensitive T1 -weighted magnetic resonance imaging (MRI) contrast agent, UMFNP-CREKA is reported. By conjugating the ultrasmall manganese ferrite nanoparticles (UMFNPs) with a tumor-targeting penta-peptide CREKA (Cys-Arg-Glu-Lys-Ala), ultrasmall breast cancer metastases are accurately detected. With a behavior similar to neutrophils' immunosurveillance process for eliminating foreign pathogens, UMFNP-CREKA exhibits a chemotactic "targeting-activation" capacity. UMFNP-CREKA is recruited to the margin of tumor metastases by the binding of CREKA with fibrin-fibronectin complexes, which are abundant around tumors, and then release of manganese ions (Mn2+ ) to the metastasis in response to pathological parameters (mild acidity and elevated H2 O2 ). The localized release of Mn2+ and its interaction with proteins affects a marked amplification of T1 -weighted magnetic resonance (MR) signals. In vivo T1 -weighted MRI experiments reveal that UMFNP-CREKA can detect metastases at an unprecedented minimum detection limit of 0.39 mm, which has significantly extended the detection limit of previously reported MRI probe
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a T1-weighted detection
|
650 |
|
4 |
|a magnetic resonance imaging (MRI)
|
650 |
|
4 |
|a metastases
|
650 |
|
4 |
|a signal-amplification
|
650 |
|
4 |
|a ultrasmall manganese ferrite nanoparticles
|
650 |
|
7 |
|a Contrast Media
|2 NLM
|
650 |
|
7 |
|a Ferric Compounds
|2 NLM
|
650 |
|
7 |
|a Fibronectins
|2 NLM
|
650 |
|
7 |
|a Manganese Compounds
|2 NLM
|
650 |
|
7 |
|a Oligopeptides
|2 NLM
|
650 |
|
7 |
|a cysteinyl-arginyl-glutamyl-lysyl-alanyl
|2 NLM
|
650 |
|
7 |
|a manganese ferrite
|2 NLM
|
650 |
|
7 |
|a Fibrin
|2 NLM
|
650 |
|
7 |
|a 9001-31-4
|2 NLM
|
650 |
|
7 |
|a Hydrogen Peroxide
|2 NLM
|
650 |
|
7 |
|a BBX060AN9V
|2 NLM
|
700 |
1 |
|
|a Zhao, Xiao
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Liu, Xiaoli
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Cheng, Keman
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Han, Xuexiang
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhang, Yinlong
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Min, Huan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Liu, Guangna
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Xu, Junchao
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shi, Jian
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Qin, Hao
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fan, Haiming
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ren, Lei
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Nie, Guangjun
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 32(2020), 4 vom: 20. Jan., Seite e1906799
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
773 |
1 |
8 |
|g volume:32
|g year:2020
|g number:4
|g day:20
|g month:01
|g pages:e1906799
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201906799
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 32
|j 2020
|e 4
|b 20
|c 01
|h e1906799
|